Carnegie acted as sole global co-ordinator and sole bookrunner in the rights issue of SEK 225 million in Intervacc.
Intervacc is a Swedish company within animal health developing vaccines for animals. The Company develops and sells vaccines against animal diseases based on the proprietary technology platform with fused recombinant proteins.